Clinical trial
A Multi-Center Randomized Phase II Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer [CA209-9FC]
NCT03101566 is registered in ClinicalTrials.gov with University of Michigan Rogel Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-Center Randomized Phase II Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer [CA209-9FC]
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 8, 2017
- Completion date
- June 7, 2021
- Enrollment
- 75 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.